2166-P: Association between Maternal Prenatal Glycated Hemoglobin and Fetal Long and Intermediate-Term Glycemic Markers

Introduction and Objective: Hyperglycemia in pregnancy is associated with maternal-fetal adverse outcomes. Examined associations between prenatal and fetal cord blood glycemic biomarkers. Methods: Clinical data, biosamples from 85-Hispanic and American Indian pregnant women and their neonate were examined (Aug 2022-Aug 2025). Biomarkers measured in matched prenatal, and fetal cord blood included total glycated hemoglobin (GlyHB), fructosamine, insulin, Cpeptide, cortisol, hsCRP, APOC3, RBP4, FGF21, leptin, adiponectin. Results: Maternal-GlyHB was positively correlated with fetal biomarkers GlyHB (r=0.44, P<0.001), fructosamine (r=0.28, P<0.05), insulin (r=0.22, P<0.05), Cpeptide (r=0.35, P<0.01), leptin (r=0.33, P<0.01) (Fig1). Multiple linear regression analysis showed that prenatal-GlyHB (β: 0.385; [ 95% CI: 0.076-0.693], P=0.015) was significantly associated with fetal-GlyHB, pregestational BMI did not moderate this relationship. Correlation between maternal and fetal-GlyHB did not differ significantly from that between fetal-GlyHB and 1-hr glucose, following 50 gm oral glucose loading test (Δr=0.17; Z=1.83; p=0.067). Conclusion: Maternal-fetal long and intermediate term biomarker associations were significant, and independent of maternal adiposity. Prenatal-GlyHB and 1-hr glucose showed comparable correlations with fetal-GlyHB, indicating the role of prenatal-GlyHB as viable marker of sustained in utero glycemic exposure. Disclosure S. Roy Choudhury: None. D.B. Sacks: Other - Crada; Current; Sebia. R.L. Hanson: None. M. Sampson: None. R. Caballero: None. D. Wasak: None. Z.S. Coleman: None. Y.L. Muller: None. M. Sinha: None. Funding National Institute of Diabetes and Digestive and Kidney Diseases (Intramural Research Program)